Nổi bật :

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Globenewswire -

Curium Establishes Legal Entity in China

Curium Establishes Legal Entity in China

Globenewswire -

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globenewswire -

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Globenewswire -

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Globenewswire -

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Globenewswire -

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Globenewswire -

XEM THÊM TIN MỚI
MỚI NHẤT
So sánh màn hình LG với Samsung và ViewSonic: Đâu là lựa chọn tối ưu?

So sánh màn hình LG với Samsung và ViewSonic: Đâu là lựa chọn tối ưu?

Mua Đồ Công Nghệ Trả Góp: Hướng Dẫn So Sánh và Chọn Lựa Thông Minh

Mua Đồ Công Nghệ Trả Góp: Hướng Dẫn So Sánh và Chọn Lựa Thông Minh

Lưu ngay cách gỡ bỏ phương thức thanh toán trên iPhone cực hiệu quả

Lưu ngay cách gỡ bỏ phương thức thanh toán trên iPhone cực hiệu quả

Giải mã thần số học nghề nghiệp 2025 chi tiết, chuẩn xác

Giải mã thần số học nghề nghiệp 2025 chi tiết, chuẩn xác

Bảng Quy đổi chữ cái thần số học là gì và cách chuyển đổi

Bảng Quy đổi chữ cái thần số học là gì và cách chuyển đổi

QUAN TÂM
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

BitMEX Launches Equity Perps for 24/7 Stock Trading

BitMEX Launches Equity Perps for 24/7 Stock Trading

Mark Your Calendar: Hong Kong to Host Asia’s 50 Best Restaurants 2026 after Historic Double Win

Mark Your Calendar: Hong Kong to Host Asia’s 50 Best Restaurants 2026 after Historic Double Win

Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

Treasure Global Concludes Alumni Capital Equity Line Facility to Streamline Capital Structure and Focus on Fintech & Digital-Asset Growth

Treasure Global Concludes Alumni Capital Equity Line Facility to Streamline Capital Structure and Focus on Fintech & Digital-Asset Growth